Business Description
Solid Biosciences Inc
NAICS : 325411
SIC : 2836
ISIN : US83422E2046
Total Employee Number:
121Description
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 18.42 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 43.7 | |||||
3-Year EPS without NRI Growth Rate | 44.8 | |||||
3-Year FCF Growth Rate | 46.7 | |||||
3-Year Book Growth Rate | -40.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.57 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90.85 | |||||
9-Day RSI | 83.81 | |||||
14-Day RSI | 77.34 | |||||
3-1 Month Momentum % | -12.15 | |||||
6-1 Month Momentum % | 20.73 | |||||
12-1 Month Momentum % | 35.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.1 | |||||
Quick Ratio | 13.1 | |||||
Cash Ratio | 12.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -59.2 | |||||
Shareholder Yield % | -22.59 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -72.38 | |||||
ROA % | -60.63 | |||||
ROIC % | -461.61 | |||||
3-Year ROIIC % | 1832.88 | |||||
ROC (Joel Greenblatt) % | -723.26 | |||||
ROCE % | -68.04 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.85 | |||||
Price-to-Tangible-Book | 2.85 | |||||
EV-to-EBIT | -3.65 | |||||
EV-to-EBITDA | -3.68 | |||||
EV-to-FCF | -4.09 | |||||
| Price-to-Net-Current-Asset-Value | 3.06 | |||||
| Price-to-Net-Cash | 3.22 | |||||
Earnings Yield (Greenblatt) % | -27.4 | |||||
FCF Yield % | -16.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLDB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Solid Biosciences Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.95 | ||
| Beta | 2.4733 | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 1.02 | ||
| Volatility % | 61.61 | ||
| 14-Day RSI | 77.34 | ||
| 14-Day ATR ($) | 0.619622 | ||
| 20-Day SMA ($) | 8.1475 | ||
| 12-1 Month Momentum % | 35.11 | ||
| 52-Week Range ($) | 3.79 - 10.875 | ||
| Shares Outstanding (Mil) | 98.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Solid Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Solid Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-03 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 39 days | ||
| General meeting for 2026 | 2026-06-10 08:00 | 6.57 (+1.23%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 16:00 | 6.70 (-6.56%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 07:35 | 6.58 (-6.80%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 7.68 (+4.77%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 14:15 | 8.39 (+4.74%) | ||
| Annual report for 2025 | 2026-03-19 | 7.12 (-6.81%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 7.12 (-6.81%) | ||
| Guidance call for 2026 | 2026-02-12 10:30 | 6.40 (-7.25%) |
Show
Entries
Solid Biosciences Inc Frequently Asked Questions
What is Solid Biosciences Inc(SLDB)'s stock price today?
The current price of SLDB is $10.84. The 52 week high of SLDB is $10.88 and 52 week low is $3.79.
When is next earnings date of Solid Biosciences Inc(SLDB)?
The next earnings date of Solid Biosciences Inc(SLDB) is 2026-08-12 Est..
Does Solid Biosciences Inc(SLDB) pay dividends? If so, how much?
Solid Biosciences Inc(SLDB) does not pay dividend.
Guru Commentaries on NAS:SLDB
No articles.
Press Release
Articles on Solid Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers